This metabolic adaptation, combined with tolerance to semaglutide, creates the ideal conditions for a plateau
Injectable Wegovy produced an average weight loss of around 15 percent in major trials, while tirzepatide, sold as Zepbound for obesity, has produced around 20 percent or more weight loss depending on dose and population
doi: 10.3389/fendo.2020.00160 Summary Keywords antioxidants, female infertility, male infertility, reactive oxygen species, oxidative stress Citation Saleh R, Sallam H, Elsuity MA, Dutta S, Sengupta P and Nasr A (2025) Antioxidant therapy for infertile couples: a comprehensive review of the current status and consideration of future prospects
No, clinical trials extending beyond 72 weeks show that tirzepatide continues to maintain its glucose-lowering and weight management effects without developing true pharmacological tolerance